Contract facts
UnrestrictedNo full NAICS 541714 intel page yet. Browse NAICS intelligence
Extend CLIN0001/Base Through December 31, 2026, Provide Supplemental Funding to Support the Development of Intramuscula… is a federal Unrestricted award for Barda - Aspr / Daappo / Barda Dcma held by Enalare Therapeutics Inc. Estimated value $50.3M ($12.2M obligated). Current period of performance ends Dec 31, 2026 (potential Sep 30, 2028). Last award drew 1 bidder. Place of performance: PRINCETON NJ. Related solicitation BAA-18-100-SOL-00003.
Extend clin0001/base through december 31, 2026, provide supplemental funding to support the development of intramuscular (im) ena-001 for submission to the us food and drug administration, update section i.1 fed. Latest action is a modification.
Recompete timing
PublicCurrent PoP ends Dec 31, 2026 (75 days remaining). Agencies typically plan 12–18 months ahead — at 2.5 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 75A50122C00072? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordEnalare Therapeutics Inc — $6.3M obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50122C00072?
75A50122C00072 (Extend clin0001 base through december 31) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $50.3M, currently held by Enalare Therapeutics Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50122C00072?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50122C00072 to Enalare Therapeutics Inc (potential $50.3M).
Who is the incumbent on 75A50122C00072?
Enalare Therapeutics Inc is the incumbent with $6.3M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2026.
When does Enalare Therapeutics Inc’s 75A50122C00072 come up for recompete?
SCOUT tracks a period-of-performance end of Dec 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75A50122C00072? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.